Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector

Engineered DNA-binding proteins that manipulate the human genome and transcriptome have enabled rapid advances in biomedical research. In particular, the RNA-guided CRISPR/Cas9 system has recently been engineered to create site-specific double-strand breaks for genome editing or to direct targeted transcriptional regulation. A unique capability of the CRISPR/Cas9 system is multiplex genome engineering by delivering a single Cas9 enzyme and two or more single guide RNAs (sgRNAs) targeted to distinct genomic sites. This approach can be used to simultaneously create multiple DNA breaks or to target multiple transcriptional activators to a single promoter for synergistic enhancement of gene induction. To address the need for uniform and sustained delivery of multiplex CRISPR/Cas9-based genome engineering tools, we developed a single lentiviral system to express a Cas9 variant, a reporter gene and up to four sgRNAs from independent RNA polymerase III promoters that are incorporated into the vector by a convenient Golden Gate cloning method. Each sgRNA is efficiently expressed and can mediate multiplex gene editing and sustained transcriptional activation in immortalized and primary human cells. This delivery system will be significant to enabling the potential of CRISPR/Cas9-based multiplex genome engineering in diverse cell types.

[1]  Lei Zhang,et al.  Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. , 2010, Genome research.

[2]  Randall J. Platt,et al.  Optical Control of Mammalian Endogenous Transcription and Epigenetic States , 2013, Nature.

[3]  Carlos F. Barbas,et al.  Regulation of Endogenous Human Gene Expression by Ligand-Inducible TALE Transcription Factors , 2013, ACS synthetic biology.

[4]  Christopher M. Vockley,et al.  RNA-guided gene activation by CRISPR-Cas9-based transcription factors , 2013, Nature Methods.

[5]  P. Mali,et al.  Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. , 2011, Blood.

[6]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[7]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[8]  Yunde Zhao,et al.  Self-processing of ribozyme-flanked RNAs into guide RNAs in vitro and in vivo for CRISPR-mediated genome editing. , 2014, Journal of integrative plant biology.

[9]  G. Church,et al.  CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering , 2013, Nature Biotechnology.

[10]  Luigi Naldini,et al.  Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery , 2007, Nature Biotechnology.

[11]  D. Trono,et al.  Production and titration of lentiviral vectors. , 2006, Current protocols in neuroscience.

[12]  Martin J. Aryee,et al.  Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing , 2014, Nature Biotechnology.

[13]  Morgan L. Maeder,et al.  In Situ Genetic Correction of the Sickle Cell Anemia Mutation in Human Induced Pluripotent Stem Cells Using Engineered Zinc Finger Nucleases , 2011, Stem cells.

[14]  C. Barbas,et al.  Synthetic Zinc Finger Proteins: The Advent of Targeted Gene Regulation and Genome Modification Technologies , 2014, Accounts of chemical research.

[15]  C. Gersbach,et al.  Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression. , 2014, Methods.

[16]  Y. Ohshima,et al.  Nucleotide sequences of mouse genomic loci including a gene or pseudogene for U6 (4.8S) nuclear RNA. , 1981, Nucleic acids research.

[17]  Albert Jeltsch,et al.  Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. , 2013, Journal of molecular biology.

[18]  D. Persons Lentiviral vector gene therapy: effective and safe? , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[20]  C. Gersbach,et al.  Advances in targeted genome editing. , 2012, Current opinion in chemical biology.

[21]  R. Maehr,et al.  Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells , 2014, Development.

[22]  Jeffry D. Sander,et al.  CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.

[23]  T. Weng,et al.  A novel approach for the construction of multiple shRNA expression vectors , 2007, The journal of gene medicine.

[24]  Christof von Kalle,et al.  TALEN-based gene correction for epidermolysis bullosa. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  C C Case,et al.  Regulation of an Endogenous Locus Using a Panel of Designed Zinc Finger Proteins Targeted to Accessible Chromatin Regions , 2001, The Journal of Biological Chemistry.

[26]  J. Keith Joung,et al.  Robust, synergistic regulation of human gene expression using TALE activators , 2013, Nature Methods.

[27]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[28]  C C Case,et al.  Synthetic Zinc Finger Transcription Factor Action at an Endogenous Chromosomal Site , 2000, The Journal of Biological Chemistry.

[29]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[30]  C. Gersbach,et al.  Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine , 2014, Expert opinion on therapeutic targets.

[31]  Charles A Gersbach,et al.  Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  Eric P. Bennett,et al.  High-efficiency genome editing via 2A-coupled co-expression of fluorescent proteins and zinc finger nucleases or CRISPR/Cas9 nickase pairs , 2014, Nucleic acids research.

[33]  Farshid Guilak,et al.  Synergistic and tunable human gene activation by combinations of synthetic transcription factors , 2013, Nature Methods.

[34]  Jeffrey C. Miller,et al.  A rapid and general assay for monitoring endogenous gene modification. , 2010, Methods in molecular biology.

[35]  L. Nissim,et al.  Multiplexed and programmable regulation of gene networks with an integrated RNA and CRISPR/Cas toolkit in human cells. , 2014, Molecular cell.

[36]  Jeffry D Sander,et al.  Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins , 2013, Nature Biotechnology.

[37]  Luke A. Gilbert,et al.  Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.

[38]  Seung Woo Cho,et al.  Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease , 2013, Nature Biotechnology.

[39]  Yilong Li,et al.  Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library , 2013, Nature Biotechnology.

[40]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[41]  Aviv Regev,et al.  Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing , 2014, Nature Biotechnology.

[42]  Charles A. Gersbach,et al.  Light-Inducible Spatiotemporal Control of Gene Activation by Customizable Zinc Finger Transcription Factors , 2012, Journal of the American Chemical Society.

[43]  Yarden Katz,et al.  Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system , 2013, Cell Research.

[44]  Jeffrey C. Miller,et al.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.

[45]  T. Lu,et al.  Tunable and Multifunctional Eukaryotic Transcription Factors Based on CRISPR/Cas , 2013, ACS synthetic biology.

[46]  D. Trono,et al.  Production and Titration of Lentiviral Vectors , 2006, Current protocols in neuroscience.

[47]  R. Jaenisch,et al.  Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases , 2009, Nature Biotechnology.

[48]  Charles A. Gersbach,et al.  Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases , 2011, Nucleic acids research.

[49]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[50]  J. Joung,et al.  Locus-specific editing of histone modifications at endogenous enhancers using programmable TALE-LSD1 fusions , 2013, Nature Biotechnology.

[51]  Feng Zhang,et al.  Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA , 2014, Cell.

[52]  Prashant Mali,et al.  Orthogonal Cas9 Proteins for RNA-Guided Gene Regulation and Editing , 2013, Nature Methods.

[53]  M. Melli,et al.  The in vitro transcription of the 7SK RNA gene by RNA polymerase III is dependent only on the presence of an upstream promoter , 1987, Cell.

[54]  Jennifer Doudna,et al.  RNA-programmed genome editing in human cells , 2013, eLife.

[55]  C. Barbas,et al.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.

[56]  Morgan L. Maeder,et al.  CRISPR RNA-guided activation of endogenous human genes , 2013, Nature Methods.

[57]  Hojun Li,et al.  In vivo genome editing restores hemostasis in a mouse model of hemophilia , 2011, Nature.

[58]  Jeffry D. Sander,et al.  Efficient In Vivo Genome Editing Using RNA-Guided Nucleases , 2013, Nature Biotechnology.

[59]  Kira S. Makarova,et al.  Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems , 2013, Nucleic acids research.

[60]  U. Schopfer,et al.  Chemically Regulated Zinc Finger Transcription Factors* , 2000, The Journal of Biological Chemistry.

[61]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[62]  P. Carbon,et al.  An unusually compact external promoter for RNA polymerase III transcription of the human H1RNA gene. , 2001, Nucleic acids research.